GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that potentiates glucose-stimulated insulin secretion during a meal. Since GIP has also been shown to exert β-cell prosurvival and adipocyte lipogenic effects in rodents, both GIP receptor agonists and antagonists have been considered as potential therapeutics in type 2 diabetes (T2DM). In the present study, we tested the hypothesis that chronically elevating GIP levels in a transgenic (Tg) mouse model would increase adipose tissue expansion and exert beneficial effects on glucose homeostasis. In contrast, although GIP Tg mice demonstrated enhanced β-cell function, resulting in improved glucose tolerance and insulin sensitivity, they exhibited reduced diet-induced obesity. Adipose tissue macrophage infiltration and hepatic steatosis were both greatly reduced, and a number of genes involved in lipid metabolism/inflammatory signaling pathways were found to be down-regulated. Reduced adiposity in GIP Tg mice was associated with decreased energy intake, involving overexpression of hypothalamic GIP. Together, these studies suggest that, in the context of over-nutrition, transgenic GIP overexpression has the potential to improve hepatic and adipocyte function as well as glucose homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precise effects of GIP on lipid metabolism are currently unclear; some studies suggest it may increase lipid uptake in adipose tissue and decrease lipolysis [53,54], while others suggest GIP may have lipolytic activity, as adipose tissue from transgenic mice overexpressing GIP has been found to be resistant to high-fat feeding [55,56].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [56]
In the citing paper
“Notwithstanding, significant general GIP overexpression prevents obesity and lowers inflammatory markers in mice [123].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“gastric emptying and food intake [5–9].”
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“needed [3–4].”
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 1×
“lowering carbohydrate digestion [1–2].”
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310 · cited 1×
“In a recent study, it was demonstrated that overexpression of adiponectin in mice on an ob/ob genetic background resulted in greater obesity, compared to non-transgenic animals, but with marked improvements in both glucose tolerance and insulin resistance, as well as reduced circulating TG and hepatic steatosis [31].”
BackgroundMitochondrial biogenesis in mammals: the role of endogenous nitric oxide
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S., et al. (2003) · Science · doi:10.1126/science.1079368 · Cited by 1,243 · cited 1×
“eNos has been linked to the induction of PGC-1a expression [38–39] and both PGC-1a [40] and Ucp2 [41] are involved in mitochondrial biogenesis, reduction of which may contribute to lowering ROS production.”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“No significant differences in energy expenditure, determined by indirect calorimetry, were apparent between Het GIP Tg mice and WT littermates on either LF or HF diets (Figure 5A and Figure S1), whereas higher energy expenditure was reported for GIPRKO mice [22].”
BackgroundMethodResultThe role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614 · cited 1×
“gastric emptying and food intake [5–9].”
Sethi, J. K., & Vidal-Puig, A. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700005-jlr200 · Cited by 563
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“In view of the glucose intolerance but resistance to diet-induced obesity observed in GIPR knockout mice [22,33–34], the current study was initiated to test the hypothesis that chronically elevating GIP levels in vivo would increase adipose tissue expansion and exert beneficial effects on glucose homeostasis.”
Background
Cited by
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
“Chronically elevating GIP levels in a transgenic mouse model has been shown to reduce diet-induced obesity (DIO) and improve insulin sensitivity, glucose tolerance, and beta-cell function [30].”
BackgroundUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
“Likewise, mice treated with GIP analogs (36) or with transgenic GIP overexpression (14) are also protected from diet-induced obesity.”
BackgroundTargeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345
“GIP overexpressing transgenic mice were reportedly more insulin sensitive than wild-type control mice on insulin tolerance tests, indicative of potential actions of GIP to reduce insulin resistance (27).”
BackgroundAdriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
“However, transgenic overexpression of GIP elicited a marked reduction in energy intake (Kim et al., 2012), and ICV administration of GIP reduced food intake (NamKoong et al.”
BackgroundZhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Min, T., & Bain, S. C. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 285
Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.36 · Cited by 287
Role of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
“Overexpression of GIP or administration of long-acting GIPR agonists (LAGIPRAs) enhances whole-body insulin sensitivity in models of obesity-induced IR (23, 24).”
BackgroundResultInfluentialSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Similarly, widespread transgenic Gip expression under the control of the metallothionein promoter decreased adipose tissue mass, reduced macrophage infiltration and attenuated the expression of Ccl2 , Serpin1 , Il4ra and Ikbkb , genes encoding pro-inflammatory proteins, in WAT of HFD-fed mice 68 .”
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
“On the contrary, there is experimental evidence that amplified GIP action is also beneficial to body weight, including transgenic overexpression of GIP [18], single [19] and combinatorial preclinical pharmacology [5,20e22], and genome-wide association studies [23].”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“Notably, in contrast to a series of historic studies testifying to GIP as an obesogenic hormone, mice overexpressing GIP show improved b -cell function and improved glycemic control and are resistant to diet-induced obesity (Kim et al., 2012a).”
BackgroundResultReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Transgenic overexpression of GIP Mice with conditional expression of Gip under control of metallothionein promoter hadw1000-fold increases in circulating GIP levels [87].”
BackgroundNguyen, N. Q., Debreceni, T. L., Bambrick, J. E., Chia, B., Wishart, J., Deane, A. M., Rayner, C. K., Horowitz, M., & Young, R. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3144 · Cited by 121
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Central administration of GLP-1 and GIP decreases feeding in mice
NamKoong, C., Kim, M. S., Jang, B.-T., Lee, Y. H., Cho, Y.-M., & Choi, H. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.031 · Cited by 114
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance
Ceperuelo-Mallafré, V., Duran, X., Pachón, G., Roche, K., Garrido-Sánchez, L., Vilarrasa, N., Tinahones, F. J., Vicente, V., Pujol, J., Vendrell, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3350 · Cited by 112
“Despite the fact that some animal data point to GIPR inhibition as a potential treatment for obesity (5–8), this work is somewhat controversial because beneficial effects for GIP have also been described in mice (9).”
BackgroundNutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Lu, V. B., Gribble, F. M., & Reimann, F. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 117
“By contrast, overexpression of GIP in mice also led to decreased energy intake and reduced weight gain associated with diet-induced obesity [318].”
BackgroundGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Millman, J. F., Okamoto, S., Teruya, T., Uema, T., Ikematsu, S., Shimabukuro, M., & Masuzaki, H. (2020) · Nutrition Reviews · doi:10.1093/nutrit/nuaa148 · Cited by 116
“In addition, it has been proposed that GIP may exert some of its beneficial effects on metabolic health via the central nervous system; increased expression of GIP in the hypothalamus in mice resulted in regulation of food intake, and played an important role in memory, with GIP-receptor–deficient mice exhibiting impa…”
BackgroundGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89
“The in vivo anti-inflammatory effect of GIP was suggested by studies showing reduced adipose tissue inflammatory cytokines in GIP-overexpressing transgenic mice (23) and by reduced atherosclerosis following administration of exogenous GIP (24, 25).”
BackgroundTimper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
“A recent study in GIP-overexpressing mice reported reduced adipose tissue macrophage infiltration and expression of genes involved in inflammatory signaling (35).”
BackgroundRavn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'Brien, S., Collinson, A., Papworth, M., Fritsch-Fredin, M., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 86
“Transgenic mice overexpressing GIP exhibited reduced diet-induced obesity, although excessively elevated levels led to GIP resistance (48).”
BackgroundFinan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Fukuda, M. (2021) · Diabetes · doi:10.2337/dbi21-0001 · Cited by 69
“Instead, negative energy balance is induced by administration of long-lasting GIP derivatives (28,29) or transgenic overexpression of GIP (30).”
BackgroundYu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
“75 29, 38 Here , we demonstrate demonstrate that Locally, we demonstrate that GIPR induction increases adipose tissue lipid oxidation, lipid uptake, thermogenesis, and cellular energy demand.”
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 84
Physiological roles of the GIP receptor in murine brown adipose tissue
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.006 · Cited by 70
“Nevertheless, GIPR agonism also reduces food intake in mice [27], and transgenic overexpression of GIP promotes resistance to diet-induced obesity and reduced fat mass in mice [38].”
BackgroundRizvi, A. A., & Rizzo, M. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s351982 · Cited by 65
“10 These hormones seem to work in tandem; GLP-1 inhibits glucagon secretion when plasma glucose concentration is high, while GIP acts at lower glucose levels.”
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“Inhibition of intestinal TPH1 in mice, through tissue-specific ablation or pharmacological inhibition, conveys protection from highfat diet (HFD)-induced dyslipidaemia and glucose intolerance (30–32).”
BackgroundInfluentialGIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · Diabetes · doi:10.2337/db21-1166 · Cited by 68
S100 proteins in obesity: liaisons dangereuses
Riuzzi, F., Chiappalupi, S., Arcuri, C., Giambanco, I., Sorci, G., & Donato, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03257-4 · Cited by 78
“However, augmentation of GIPR signaling in animal models of diet-induced obesity reduces adipose tissue infiltration of proinflammatory innate and adaptive immune cells [93, 94].”
BackgroundPeptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Cho, Y. K., Lee, Y. L., & Jung, C. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.3.213 · Cited by 71
Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“The genetic or pharmacological blockade of GIPR attenuates obesity development in rodents [72,73], whereas GIP overexpression reduces diet-induced obesity and improves glucose metabolism [74].”
BackgroundGIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
“Moreover, overexpression of GIP gene attenuated the gene expression levels of pro-inflammatory molecules, including Ccl2, inhibitor of nuclear factor kappa-B kinase subunit beta, Il-4 receptor alpha, Tnf receptor superfamily member 1b, and Pai-1 in the epididymal fats of HFD-fed mice [50].”
BackgroundDiabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
“Overexpression of GIP has, however, also been shown to be associated with reduced body weight in diet-induced obese (DIO) mice [21].”
BackgroundResultZhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
“Furthermore, other studies demonstrated that acute GIP infusion to human would increase adipose tissue blood flow [46], promote insulin sensitivity, glucose tolerance and β-cell function [45].”
BackgroundPharmacological Approaches in the Treatment and Maintenance of Weight Loss
Van Gaal, L., & Dirinck, E. (2016) · Diabetes Care · doi:10.2337/dcs15-3016 · Cited by 52
“Although GIP is orexogenic, GIP-overexpressing mice even show a reduced tendency to develop diet-induced obesity, contradicting the notion that the orexogenic effect of GIP results in an obesogenic effect (68).”
BackgroundZaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
Incretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“It was recently reported that whole-body overexpression of GIP reduces diet-induced obesity in mice [60 ], which is seemingly inconsistent with the working model of GIP function in fat accumulation.”
BackgroundGIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 58
Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 62
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Geisler, C. E., Antonellis, M. P., Trumbauer, W., Martin, J. A., Coskun, T., Samms, R. J., & Hayes, M. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14843 · Cited by 51
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Samms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“Surprisingly, however, mice overexpressing GIP were shown to exhibit reduced weight gain and fat mass upon feeding of a high-fat diet, and unlike the GIPR − / − mouse, they exhibited a reduction in energy intake (190).”
KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state
Ogata, H., Seino, Y., Harada, N., Iida, A., Suzuki, K., Izumoto, T., Ishikawa, K., Uenishi, E., Ozaki, N., Hayashi, Y., et al. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0161 · Cited by 42
“In addition, GIP-overexpressing mice (Kim et al. 2012) and mice with GIP hypersecretion (Fukami et al.”
BackgroundNovel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 43
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“…are currently unclear; some studies suggest it may increase lipid uptake in adipose tissue and decrease lipolysis [53,54], while others suggest GIP may have lipolytic activity, as adipose tissue from transgenic mice overexpressing GIP has been found to be resistant to high-fat feeding [55,56].”
BackgroundInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Petrus, P., Fernandez, T. L., Kwon, M., Huang, J. L., Lei, V. J., Safikhan, N., Karunakaran, S., O'Shannessy, D. J., Zheng, X., Catrina, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.057 · Cited by 40
“Food and water intake were measured for 72 h with PhenoMaster metabolic cages (TSE Systems, Bad Homburg, Germany), after a 72 h acclimatization period [25].”
MethodSelf-citationBoer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Permana, H., Yanto, T. A., & Hariyanto, T. I. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102640 · Cited by 38
Jensen, M., Sanni, S. J., Riber, D., Holst, J. J., ROSENKILDE, M. M., & Sparre‐Ulrich, A. H. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102006 · Cited by 42
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
“GIPR gene deletion in mice resulted in improved glycaemic control and in a protection against diet induced-obesity [37, 38].”
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“…GIP have focused on its insulinotropic actions and other b-cell functions, and long-term administration of DPP-IV-resistant GIP analogues showed marked improvements in glucose tolerance in normal and diabetic rats, as well as in HF fed mice (Hinke et al. 2002; Gault et al., 2011; Kim et al., 2012).”
BackgroundResultInfluentialLiu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 40
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“18 Subsequent study demonstrated the expression of GCG receptors in multiple regions in the CNS. 106 Central injection of GCG significantly inhibited food intake through the hypothalamic PKA/CaMKK β /AMPK pathway.”
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
“Loss of GIP action is therefore associated with a better outcome in diabetes and resistance towards DIO in mice [232, 233], but contradictory a transgenic overexpression of GIP also promotes resistance to DIO and leads to a reduced fat mass in mice [234].”
BackgroundRockwood, S., Mason, D., Lord, R., Lamar, P. C., Prozialeck, W. C., & Al‐Nakkash, L. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s216312 · Cited by 35
“For example, over-expression of glucose-dependent insulinotropic polypeptide (GIP) in mice has been shown to reduce diet-induced obesity and steatosis and to improve glucose homeostasis.(20) GIP, potentiates glucose-stimulated insulin secretion during a meal, and promotes nutrient uptake and storage.”
BackgroundHasib, A., Ng, M. T., Gault, V. A., Khan, D., Parthsarathy, V., Flatt, P. R., & Irwin, N. (2016) · Diabetologia · doi:10.1007/s00125-016-4186-y · Cited by 33
“Similar to the conundrum regarding the clinical use of GIP receptor agonists or antagonists, both genetic knockout [49] and overexpression [50] of GIP has been shown to protect against obesity and development of diabetes.”
Baldassano, S., Gasbjerg, L. S., Kizilkaya, H. S., ROSENKILDE, M. M., Holst, J. J., & Hartmann, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00492 · Cited by 34
“Furthermore, GIP administration reduced adipose tissue inflammation in DPP-4 deficient rats fed a HFD (18) and GIP-overexpression in transgenic mice reduced adipose tissue inflammation (19).”
BackgroundInfluentialHeimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 34
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
“In rodent models, targeting GIPR with a GIP analog [30] or a GIP antagonist had beneficial effects on adipose tissue in both cases [31–34].”
MethodRameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
“showed less weight gain and adiposity in response to high-fat diet (61).”
BackgroundKo, J., Jang, S., Kwon, W., Kim, S., Jang, S., Kim, E., Ji, Y. R., Park, S., Kim, M.-O., Choi, S., et al. (2022) · Antioxidants · doi:10.3390/antiox11020189 · Cited by 33
“Several studies have demonstrated that GIP-overexpressing mice show increased bone mass [66] and reduced obesity [67].”
BackgroundSelf-citationRenner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 35
“This was most likely due to a markedly reduced (−45%) energy intake of GIP-over-expressing compared to control mice [59].”
BackgroundThe interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
“Whole-body overexpression of GIP levels (using GIP-transgenic, heterozygous mice) has been used to evaluate fat development (Kim et al. 2012).”
MethodNogueiras, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0277 · Cited by 32
Lv, X., Wang, H., Chen, C., Zhao, Y., Li, K., Wang, Y., Wang, L., Fu, S., & Liu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443396 · Cited by 33
“20 In addition to this, GIP can increase insulin sensitivity and improve islet β-cell function in mice, 22,23 reduce steatosis 24 and promote lipid metabolism in the body, thus resulting in a reduction of free lipid substances in the blood.”
BackgroundLi, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“Together, these studies suggest that, in the context of overnutrition, transgenic GIP overexpression has the potential to improve hepatic and adipocyte function as well as glucose homeostasis (Kim et al., 2012).”
BackgroundShimazu‐Kuwahara, S., Harada, N., Yamane, S., Joo, E., Sankoda, A., Kieffer, T. J., & Inagaki, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.01.006 · Cited by 28
“Moreover, somewhat surprisingly, chronic overexpression of GIP in mice reduced diet-induced obesity and steatosis, in addition to improving glucose homeostasis [18].”
BackgroundBen‐Shlomo, S., Zvibel, I., Varol, C., Spektor, L., Shlomai, A., Santo, E. M., Halpern, Z., Oren, R., & Fishman, S. (2013) · Obesity · doi:10.1002/oby.20340 · Cited by 28
“Furthermore, inhibition of GIP binding to its receptor using 1 lM of the GIP antagonist GIP (7-30) prevents the GIP-mediated increase in adiponectin levels (Figure 5A and 5B).”
BackgroundMethodInfluentialAre peptide conjugates the golden therapy against obesity?
Brandt, S. J., Kleinert, M., Tschöp, M. H., & Müller, T. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0264 · Cited by 27
Kokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K. K., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., & Haneda, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3842-y · Cited by 26
“By inhibiting apoptosis, GIP reportedly has a protective effect on pancreatic beta cells [22, 23].”
BackgroundInfluentialMaekawa, R., Ogata, H., Murase, M., Harada, N., Suzuki, K., Joo, E., Sankoda, A., Iida, A., Izumoto, T., Tsunekawa, S., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00352.2017 · Cited by 28
“GIP potently stimulates the early-phase insulin response to glucose elevation and lowers blood glucose levels (7, 20, 41).”
BackgroundIida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3935-2 · Cited by 27
“GIP also has been reported to contribute to beta cell survival in vitro [40, 41], while GIP overexpression was found to enhance the increment of insulin content induced by high-fat diet feeding by decreasing beta cell apoptosis [39].”
Al-Zamel, N., Al‐Sabah, S., Luqmani, Y. A., Adi, L., Chacko, S., Schneider, T. D., & Krasel, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143532 · Cited by 25
“Furthermore, GIP overexpressing mice exhibit reduced diet-induced obesity and improved glucose homeostasis [30].”
BackgroundAssociation of Gut Hormones and Microbiota with Vascular Dysfunction in Obesity
Rovella, V., Rodia, G., Daniele, F. D., Cardillo, C., Campia, U., Noce, A., Candi, E., Della‐Morte, D., & Tesauro, M. (2021) · Nutrients · doi:10.3390/nu13020613 · Cited by 25
“For instance, mice overexpressing GIP are leaner than wild type [145] because more factors are involved in the control of energy balance, and this process seems to be mediated by GIP modulation of adipokines and other gut hormones secretion.”
Background
Metadata
- Authors
- Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- McIntosh, Christopher H. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-03
- Volume
- 7
- Issue
- 7
- Pages
- e40156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3388996
- OpenAlex
- W2072686461
- Cited by
- 182
- References
- 55
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 28 · 2023: 18 · 2022: 18 · 2021: 14 · 2020: 17 · 2019: 21 · 2018: 12 · 2017: 5 · 2016: 13 · 2015: 5 · 2014: 7 · 2013: 7 · 2012: 1
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Canadian Diabetes Association
- Michael Smith Health Research BC
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- glucose-dependent insulinotropic polypeptide, diet-induced obesity, hepatic steatosis, glucose homeostasis, insulin sensitivity, beta-cell function, adipose tissue macrophage infiltration, energy intake, lipid metabolism, inflammation, type 2 diabetes, transgenic mice
- MeSH terms
- Adipose Tissue, Animals, Energy Metabolism, Fatty Liver, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Homeostasis, Insulin Resistance, Male, Mice, Transgenic, Obesity, Glucose Intolerance, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.